Claims
- 1. A condensed pyrazole derivative of the Formula (1): ##STR34## wherein A is CH; R.sup.0 and R.sup.3 are the same or different, and are a hydrogen atom or a lower alkyl group, R.sup.1 and are the same or different, and are a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m is 1 or 2, and n is 1, 2 or 3, provided that, when n is 2 and the two R.sup.2 groups are adjacent, the adjacent R.sup.2 groups may be connected to form a lower alkylenedixoy group, or its pharmaceutically available salt.
- 2. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 1, wherein R.sup.0 and R.sup.3 are the same or different, and are a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, R.sup.1 and R.sup.2 are the same or different, and are a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group, a C.sub.1 -C.sub.6 alkylthio group, a nitro group or a halogen atom, m is 1 or 2, and n is 1, 2 or 3, provided that, when n is 2 and the two R.sup.2 groups are adjacent, the adjacent R.sup.2 groups may be connected to form a C.sub.1 -C.sub.4 alkylenedioxy group.
- 3. A condensed pyrazole derivative or pharmaceutically available salt according to claim 2, wherein R.sup.1 and R.sup.2 are the same or different, and are a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group or a halogen atom, m is 1, and n is 1 or 2, provided that, when n is 2 and the two R.sup.2 groups are adjacent, the adjacent R.sup.2 groups may be connected to form a C.sub.1 -C.sub.4 alkylenedioxy group.
- 4. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 3, wherein R.sup.2 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group or a halogen atom, and n is 1.
- 5. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 4, wherein R.sup.1, R.sup.0 and R.sup.3 are hydrogen atoms.
- 6. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 5, wherein R.sup.2 is a C.sub.1 -C.sub.6 alkoxy group.
- 7. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 4, wherein R.sup.0 and R.sup.3 are a hydrogen atom, and R.sup.1 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group or a halogen atom.
- 8. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 1, wherein R.sup.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or a C.sub.1 -C.sub.6 alkoxy group, and R.sup.2 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, a C.sub.1 -C.sub.6 alkoxy group, or a halogen atom, m is 1, and n is 1 or 2, provided that, when n is 2, and the two R.sup.2 groups are adjacent, the adjacent R.sup.2 groups may be bonded to form a C.sub.1 -C.sub.4 alkylenedioxy group.
- 9. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 8, wherein R.sup.0 and R.sup.3 are each a hydrogen atom, R.sup.2 is a C.sub.1 -C.sub.6 alkoxy group or a halogen atom, and n is 1.
- 10. A condensed pyrazole derivative or its pharmaceutically available salt according to claim 9, wherein R.sup.1 is a hydrogen atom, and R.sup.2 denotes a C.sub.1 -C.sub.6 alkoxy group.
- 11. A therapeutic method for inhibiting expression of actions of androgens comprising internal administration or external application of a pharmaceutical preparation containing a condensed pyrazole derivative of the Formula (1) defined in claim 1 or its pharmaceutically available salt.
- 12. A pharmaceutical composition to be used as an androgen inhibitor comprising a therapeutically effective amount of a condensed pyrazole derivative of the Formula (1): ##STR35## wherein A is CH, R.sup.0 and R.sup.3 are the same or different, and are a hydrogen atom or a lower alkyl group, R.sup.1 and R.sup.2 are the same or different, and are a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a nitro group or a halogen atom, m is 1 or 2, and n is 1, 2 or 3, provided that, when n is 2 and the two R.sup.2 groups are adjacent, the adjacent R.sup.2 group may be connected to form a lower alkylenedioxy group), or its pharmaceutically available salt, and a pharmaceutically available carrier.
Priority Claims (2)
Number |
Date |
Country |
Kind |
4-281446 |
Oct 1992 |
JPX |
|
5-045424 |
Mar 1993 |
JPX |
|
Parent Case Info
This is a Divisional of U.S. appln. No. 08/138,113, filed Oct. 20, 1993, now U.S. Pat. No. 5,409,928.
Foreign Referenced Citations (2)
Number |
Date |
Country |
0503099 |
Sep 1992 |
EPX |
1359563 |
Jul 1974 |
GBX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
138113 |
Oct 1993 |
|